文献速递乳腺癌

循环肿瘤细胞计数指导一线治疗选择在激素受体阳性、ERBB2阴性转移性乳腺癌中的疗效:STIC CTC随机临床试验

Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

STIC CTC试验纳入755例激素受体阳性、ERBB2阴性转移性乳腺癌患者,随机分为医生驱动治疗选择组和循环肿瘤细胞(CTC)计数驱动治疗选择组。CTC组根据CTC计数(≥5 CTCs/7.5 mL则化疗,<5则内分泌治疗)选择一线方案。结果显示CTC组中位无进展生存期(PFS)为15.5个月,标准组为13.9个月,风险比0.94(90% CI 0.81-1.09),达到非劣效性,提示CTC计数可作为指导化疗与内分泌治疗选择的可靠生物标志物。

要点

  • CTC计数指导一线治疗选择非劣效于医生选择,HR 0.94(90% CI 0.81-1.09)。
  • CTC组中位PFS 15.5个月,标准组13.9个月。
  • CTC组37%接受化疗,标准组27%接受化疗。

核心结论

  • 在激素受体阳性、ERBB2阴性转移性乳腺癌中,CTC计数驱动的一线治疗选择非劣效于医生驱动选择。
  • CTC计数可能是指导化疗与内分泌治疗选择的可靠生物标志物方法。

研究设计与样本

  • STIC CTC为随机、开放标签、非劣效性3期试验,在17个法国癌症中心开展。
  • 符合条件者为18岁及以上、激素受体阳性、ERBB2阴性转移性乳腺癌的绝经前和绝经后女性。
  • 数据收集时间为2012年2月1日至2016年7月28日,分析时间为2019年6月至2019年10月。
  • 符合方案人群共755例女性,CTC组377例,标准组378例。
  • 主要终点为研究者评估的符合方案人群的PFS,非劣效性界值为风险比90% CI上限1.25。

主要发现

  • CTC组中位年龄64岁(范围30-88),标准组63岁(范围31-87)。
  • CTC组138例(37%)接受化疗,标准组103例(27%)接受化疗。
  • CTC组中位PFS为15.5个月(95% CI 12.7-17.3),标准组为13.9个月(95% CI 12.2-16.3)。
  • 主要终点达到非劣效性,风险比0.94(90% CI 0.81-1.09)。

关键数值与推荐

  • CTC驱动组中,CTC≥5 CTCs/7.5 mL者接受化疗,CTC<5 CTCs/7.5 mL者接受内分泌治疗。
  • 对照组由研究者决定一线治疗选择。
  • 非劣效性判定标准为风险比90% CI上限不超过1.25。

临床怎么用

  • 对于激素受体阳性、ERBB2阴性转移性乳腺癌患者,可考虑采用CTC计数(≥5 CTCs/7.5 mL)辅助决定一线化疗或内分泌治疗。
  • CTC计数驱动策略可能减少不必要的化疗暴露,同时不损害PFS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The choice between chemotherapy and endocrine therapy as first-line treatment for hormone receptor-positive, ERBB2 (also known as HER2)-negative metastatic breast cancer is usually based on the presence of clinical features associated with a poor prognosis. In this setting, a high circulating tumor cell (CTC) count (≥5 CTCs/7.5 mL) is a strong adverse prognostic factor for overall survival and progression-free survival (PFS). OBJECTIVE: To compare the efficacy of a clinician-driven treatment choice vs a CTC-driven choice for first-line treatment. INTERVENTIONS: In the CTC arm, patients received chemotherapy or endocrine therapy according to the CTC count (chemotherapy if ≥5 CTCs/7.5 mL; endocrine therapy if <5 CTCs/7.5 mL), whereas in the control arm, the choice was left to the investigator. DESIGN, SETTING, AND PARTICIPANTS: In the STIC CTC randomized, open-label, noninferiority phase 3 trial, participants were randomized to a clinician-driven choice of first-line treatment or a CTC count-driven first-line treatment choice. Eligible participants were premenopausal and postmenopausal women 18 years or older diagnosed with hormone receptor-positive, ERBB2-negative metastatic breast cancer. Data were collected at 17 French cancer centers from February 1, 2012, to July 28, 2016, and analyzed June 2019 to October 2019. MAIN OUTCOME AND MEASURES: The primary end point was the investigator-assessed PFS in the per-protocol population, with a noninferiority margin of 1.25 for the 90% CI of the hazard ratio. RESULTS: Among the 755 women in the per-protocol population, the median (range) age was 63 (30-88) years [64 (30-88) years for the 377 patients allocated to the CTC arm and 63 (31-87) years for the 378 patients allocated to the standard arm]; 138 (37%) and 103 (27%) received chemotherapy, respectively. Median PFS was 15.5 months (95% CI, 12.7-17.3) in the CTC arm and 13.9 months (95% CI, 12.2-16.3) in the standard arm. The primary end point was met, with a hazard ratio of 0.94 (90% CI, 0.81-1.09). CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that the CTC count may be a reliable biomarker method for guiding the choice between chemotherapy and endocrine therapy as the first-line treatment in hormone receptor-positive, ERBB2-negative metastatic breast cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01710605.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Bidard FC, Jacot W, Kiavue N, et al. Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33151266. doi:10.1001/jamaoncol.2020.5660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。